Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96L73

UPID:
NSD1_HUMAN

ALTERNATIVE NAMES:
Androgen receptor coactivator 267 kDa protein; Androgen receptor-associated protein of 267 kDa; H3-K36-HMTase; Lysine N-methyltransferase 3B; Nuclear receptor-binding SET domain-containing protein 1

ALTERNATIVE UPACC:
Q96L73; Q96PD8; Q96RN7

BACKGROUND:
Histone-lysine N-methyltransferase, H3 lysine-36 specific, functions as a histone methyltransferase that targets Lys-36 of histone H3, playing a crucial role in the regulation of DNA transcription. Known by several names, including Lysine N-methyltransferase 3B, it acts as a transcriptional intermediary factor that can either repress or activate transcription depending on the cellular context.

THERAPEUTIC SIGNIFICANCE:
This protein's malfunction is linked to diseases such as Sotos syndrome, with symptoms including intellectual disability and craniofacial abnormalities, and Beckwith-Wiedemann syndrome, associated with growth abnormalities. Targeting Histone-lysine N-methyltransferase, H3 lysine-36 specific, offers a promising avenue for developing treatments for these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.